#Biomarker Discovery

[creativeera]

Cancer Biomarkers Market is Trending by Increasing Personalized Care

Cancer biomarkers are biological molecules found in blood, tissues, or other body fluids whose presence indicates normal or abnormal processes, or conditions of concern regarding health. They are used in patient diagnosis, staging, treatment selection, monitoring of cancer progression or recurrence. Cancer biomarkers help in early cancer detection and assessing the likelihood of cancer recurrence after treatment. They play an important role in cancer risk assessment, screening, diagnosis, prognosis, and predicting treatment response for a variety of cancers. With increasing technological advancements, more personalized and targeted treatment options are emerging. This is fueling the demand for cancer biomarkers to help physicians detect cancer in early stages, determine the best treatment for each patient, monitor the effectiveness of treatment, and check for signs of recurrence.

The Global Cancer Biomarkers Market is estimated to be valued at US$ 25.60 billion in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Cancer Biomarkers are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. The increasing prevalence of cancer globally has boosted the usage of cancer biomarkers. Rising demand for non-invasive diagnostic techniques along with increasing funding for cancer research are fueling the market growth. Growing awareness regarding the benefits of early detection of cancer is further driving the demand for cancer biomarkers. The growing Cancer Biomarkers Market demand for personalized medicine is also propelling the demand for cancer biomarkers. Personalized medicine focuses on classifying individuals based on their susceptibility and likely response to particular treatment. This allows clinicians to choose the most safe and effective treatment for each patient. Many companies are increasingly investing in biomarker research and development to introduce innovative cancer diagnostics and targeted therapies. The increasing global incidence of cancer has encouraged market players to expand their geographical presence. Emerging countries in Asia Pacific and Latin America offer lucrative opportunities for players due to growing healthcare investments, favorable government policies, and rising patient disposable incomes in these regions. Players are also focusing on partnerships, mergers, acquisitions, and collaborations with research institutes and biotechs to strengthen their product portfolios and geographical footprints. Market Key Trends Next-generation sequencing (NGS) has emerged as a key trend in the global cancer biomarkers market. NGS helps to discover and validate novel biomarkers by generating huge amounts of DNA sequence data from tumor and normal samples. It allows comprehensive genomic profiling of tumors to guide treatment decisions. NGS enables the analysis of multiple biomarkers simultaneously compared to traditional techniques. This allows physicians to obtain a complete molecular profile of the tumor specific to each patient for precision diagnosis and treatment selection.

Porter’s Analysis Threat of new entrants: High capital requirements and strong intellectual property rights protections limit new entrants in this competitive market.

Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over biotech companies developing novel biomarkers, putting pricing pressure.

Bargaining power of suppliers: Suppliers of analytical instruments and clinical testing kits have some bargaining power as they provide core tools and technologies needed by most companies in this space.

Threat of new substitutes: Biomarkers able to better diagnose, monitor, or predict therapeutic responses could emerge as substitutes over time.

Competitive rivalry: Intense competition exists among large pharmaceutical companies and smaller biotech firms to develop and commercialize novel cancer biomarker diagnostic tests and services. Geographical Regions North America currently accounts for the largest share of the global cancer biomarkers market, in terms of value, owing to the high adoption of advanced cancer diagnostic techniques and presence of leading biomarker testing companies in the region. The Asia Pacific market is expected to grow at the fastest rate during the forecast period, due to growing awareness regarding early cancer detection, increasing healthcare expenditure, and expanding base of pharma & biotech companies in China, India, and other Asia Pacific countries.

Get more insights on Cancer Biomarkers Market

For Deeper Insights, Find the Report in the Language that You want

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[market-insider]

Unraveling the Intricacies of the Molecular Diagnostics Market and its Future Prospects

The global molecular diagnostics market size is expected to reach USD 17.97 billion by 2030, and expanding at a CAGR of 4.5% from 2024 to 2030, according to a recent study by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

Molecular Diagnostics Market Report Highlights

The reagents segment dominated the market and accounted for a share of 62.2% of the global revenue in 2023. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.

The polymerase chain reaction technology segment accounted for the largest revenue share in 2023. This is attributed to its use in detecting COVID-19 and other infectious diseases.

The infectious diseases segment accounted for the largest revenue share in 2023. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.

The central laboratories segment dominated the industry in 2023 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.

North America dominated the market and accounted for a 39.3% share in 2023. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.

Asia Pacific is anticipated to exhibit significant growth from 2024 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.

For More Details or Sample Copy please visit link @: Molecular Diagnostics Market Report

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

#MolecularDiagnostics #PrecisionMedicine #HealthcareInnovation #GenomicTesting #DiagnosticsTechnology #Biotechnology #PersonalizedMedicine #DiagnosticRevolution #NGS #BiomarkerDiscovery #InfectiousDiseaseDiagnosis #CancerDetection #Theranostics #Bioinformatics #MolecularBiology #DiagnosticTrends #MedicalTechnology #LaboratoryTesting #PointofCareDiagnostics #HealthTechInnovation

[global-research-report]

Outsourcing the Future of Precision Medicine: Biomarker Discovery Market Insights

Biomarker Discovery Outsourcing Services Market  Overview

The global biomarker discovery outsourcing services market size is expected to reach USD 41.27 billion by 2030, growing at a CAGR of 19.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market. Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth.

Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research. 

Biomarker Discovery Outsourcing Services Market Report Highlights

Based on biomarker type, the surrogate endpoints segment accounted for the largest revenue share of 54.88% in 2024.

Based on therapeutic areas, the market includes oncology, neurology, cardiology, autoimmune diseases, and others.

Based on the discovery phase, in 2024, the biomarker identification segment accounted for the largest revenue share in the market.

Based on end use, the market is segmented into pharmaceutical companies, biotechnology companies, and others.

The biomarker discovery outsourcing services industry in North America accounted for the largest market share of 43.96% in 2024.

Curious about the Biomarker Discovery Outsourcing Services Market? Get a FREE sample copy of the full report and gain valuable insights.

Biomarker Discovery Outsourcing Services Market Segmentation

Grand View Research has segmented the global biomarker discovery outsourcing services market on the basis of biomarker type, therapeutic area, discovery phase, end use, and region:

Biomarker Discovery Outsourcing Services Biomarker Type Outlook (Revenue, USD Million, 2018 - 2030)

Predictive Biomarkers

Prognostic Biomarkers

Safety Biomarkers

Surrogate Endpoints

Biomarker Discovery Outsourcing Services Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

Oncology

Neurology

Cardiology

Autoimmune Diseases

Other Therapeutic Area

Biomarker Discovery Outsourcing Services Discovery Phase Outlook (Revenue, USD Million, 2018 - 2030)

Biomarker Identification

Biomarker Validation

Biomarker Profiling

Biomarker Panel Development

Biomarker Selection

Biomarker Discovery Outsourcing Services End Use Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical Companies

Biotechnology Companies

Other End Use

Biomarker Discovery Outsourcing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Key Players of Biomarker Discovery Outsourcing Services Market

LabCorp

Charles River Laboratories International, Inc.

Eurofins Scientific

Celerion

ICON plc

Parexel International (MA) Corporation

Proteome Sciences

GHO Capital

Thermo Fisher Scientific Inc.

Evotec

Order a free sample PDF of the Biomarker Discovery Outsourcing Services Market Intelligence Study, published by Grand View Research.

The global biomarker discovery outsourcing services market size is expected to reach USD 41.27 billion by 2030, growing at a CAGR of 19.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The expansion of outsourced biomarker research, attributed to the increased utilization of biomarkers in clinical trials and the accelerating level of outsourcing undertaken by pharmaceutical firms are key growth factors for this market. Furthermore, increasing adoption of liquid biopsies is expected to drive the market growth.

Liquid biopsies, which involve the analysis of biomarkers in bodily fluids like blood, urine, and cerebrospinal fluid, offer several advantages over traditional tissue biopsies, such as being less invasive and providing real-time information. As a result, the adoption of liquid biopsies has been growing rapidly, and this trend directly impacts the demand for biomarker discovery outsourcing services.

Advancements in omics technologies are expected to drive market growth in the coming years. Progress in genomics, proteomics, metabolomics, and other omics technologies has enabled the identification of novel biomarkers.Integrating data from many omics disciplines can often be advantageous for biomarker identification. This all-encompassing approach enables a more thorough comprehension of complex disorders and can result in identifying reliable, multidimensional biomarkers.Outsourcing services specializing in multi-omics data integration offer valuable expertise in this area.

An increase in drug development and clinical trials is a major contributing factor to the market growth. Biomarkers play a crucial role in drug development, helping pharmaceutical companies identify suitable drug targets, streamline clinical trial processes, and select patient populations for trials.As of 2023, the global clinical trial landscape boasts 452,604 registered trials on ClinicalTrials.gov, with 64,838 actively enrolling participants. This reflects a notable surge compared to the roughly 365,000 registered trials documented in early 2021, underscoring the robust and ongoing growth within the field of clinical research. 

Biomarker Discovery Outsourcing Services Market Report Highlights

Based on biomarker type, the surrogate endpoints segment accounted for the largest revenue share of 54.88% in 2024.

Based on therapeutic areas, the market includes oncology, neurology, cardiology, autoimmune diseases, and others.

Based on the discovery phase, in 2024, the biomarker identification segment accounted for the largest revenue share in the market.

Based on end use, the market is segmented into pharmaceutical companies, biotechnology companies, and others.

The biomarker discovery outsourcing services industry in North America accounted for the largest market share of 43.96% in 2024.

Curious about the Biomarker Discovery Outsourcing Services Market? Get a FREE sample copy of the full report and gain valuable insights.

Biomarker Discovery Outsourcing Services Market Segmentation

Grand View Research has segmented the global biomarker discovery outsourcing services market on the basis of biomarker type, therapeutic area, discovery phase, end use, and region:

Biomarker Discovery Outsourcing Services Biomarker Type Outlook (Revenue, USD Million, 2018 - 2030)

Predictive Biomarkers

Prognostic Biomarkers

Safety Biomarkers

Surrogate Endpoints

Biomarker Discovery Outsourcing Services Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

Oncology

Neurology

Cardiology

Autoimmune Diseases

Other Therapeutic Area

Biomarker Discovery Outsourcing Services Discovery Phase Outlook (Revenue, USD Million, 2018 - 2030)

Biomarker Identification

Biomarker Validation

Biomarker Profiling

Biomarker Panel Development

Biomarker Selection

Biomarker Discovery Outsourcing Services End Use Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical Companies

Biotechnology Companies

Other End Use

Biomarker Discovery Outsourcing Services Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Key Players of Biomarker Discovery Outsourcing Services Market

LabCorp

Charles River Laboratories International, Inc.

Eurofins Scientific

Celerion

ICON plc

Parexel International (MA) Corporation

Proteome Sciences

GHO Capital

Thermo Fisher Scientific Inc.

Evotec

Order a free sample PDF of the Biomarker Discovery Outsourcing Services Market Intelligence Study, published by Grand View Research.

[expopeak]

Annual Immuno-Oncology Summit 2024

[mysticalpeacenut]

Depixus: Unveiling the Secrets of Life with MAGNA™ Technology

Imagine peering into the nanoscale realm, where delicate biomolecules like proteins and DNA orchestrate the symphony of life. MAGNA™ grants scientists this very ability, allowing them to observe and measure the forces at play in these crucial interactions. This unprecedented level of detail opens a treasure trove of possibilities for understanding the mechanisms of disease and designing targeted therapies.

But MAGNA™’s potential extends far beyond disease research. This versatile platform can also be used to study protein-protein interactions in healthy cells, furthering our understanding of fundamental biological processes. Additionally, it can be employed in drug discovery pipelines, accelerating the identification of promising drug candidates.

The implications of MAGNA™ are truly staggering. This revolutionary technology has the power to transform our understanding of life at its most fundamental level, paving the way for a future of personalized medicine and groundbreaking scientific discoveries. Depixus is at the forefront of this revolution, and with MAGNA™ in hand, they are poised to write a new chapter in the story of human health.

[scichores]

Fascinating Role of Genomics in Drug Discovery and Development

This article dives deep into the significance of genomics in drug discovery and development, highlighting well-known genomic-based drug development services that are driving the future of pharmaceutical therapies. #genomics #drugdiscovery

A scientist using a whole genome DNA sequencer, in order to determine the “DNA fingerprint” of a specific bacterium. Original image sourced from US Government department: Public Health Image Library, Centers for Disease Control and Prevention. Under US law this image is copyright free, please credit the government department whenever you can”. by Centers for Disease Control and Prevention is…

[covid-safer-hotties]

Alzheimer's-like brain changes found in long COVID patients - Published Sept 2, 2024

New research from the University of Kentucky's Sanders-Brown Center on Aging shows compelling evidence that the cognitive impairments observed in long COVID patients share striking similarities with those seen in Alzheimer's disease and related dementias.

The study, published in Alzheimer's & Dementia, highlights a potential commonality in brain disorders across these conditions that could pave the way for new avenues in research and treatment.

The study was a global effort, and brought together experts from various fields of neuroscience. Researchers at the UK College of Medicine led the study, including Yang Jiang, Ph.D., professor in the Department of Behavioral Science; Chris Norris, Ph.D., professor in the Department of Pharmacology and Nutritional Sciences; and Bob Sompol, Ph.D., assistant professor in the Department of Pharmacology and Nutritional Sciences. Their work focuses on electrophysiology, neuroinflammation, astrocytes and synaptic functions.

"This project benefited greatly from interdisciplinary collaboration," Jiang said. "We had input from experts, associated with the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), across six countries, including the U.S., Turkey, Ireland, Italy, Argentina and Chile."

Jiang and the collaborative team focused their work on understanding the "brain fog" that many COVID-19 survivors experience, even months after recovering from the virus. This fog includes memory problems, confusion and difficulty concentrating. According to Jiang, "The slowing and abnormality of intrinsic brain activity in COVID-19 patients resemble those seen in Alzheimer's and related dementias."

This research sheds light on the connection between the two conditions, suggesting that they may share underlying biological mechanisms. Both long COVID and Alzheimer's disease involve neuroinflammation, the activation of brain support cells known as astrocytes and abnormal brain activity. These factors can lead to significant cognitive impairments, making it difficult for patients to think clearly or remember information.

The idea that COVID-19 could lead to Alzheimer's-like brain changes is a significant development.

"People don't usually connect COVID-19 with Alzheimer's disease," Jiang said. "But our review of emerging evidence suggests otherwise."

The research reveals that the cognitive issues caused by COVID-19 reflect similar underlying brain changes as those in dementia. The study's insights emphasize the importance of regular brain function check-ups for these populations, particularly through the use of affordable and accessible tools like electroencephalography (EEG).

The study not only highlights the shared traits between long COVID and Alzheimer's, but also points to the importance of further research.

"The new insight opens avenues for future research and clinical practice, particularly in studying brain oscillations related to neural biomarkers of mild cognitive impairment in people with long COVID," said Jiang.

One of the key findings is the role of astrocytes—support cells in the brain that have not been as thoroughly studied as neurons. The research suggests that damage or activation of these cells by COVID-19 can cause synaptic dysfunctions, leading to the abnormal brain activity observed in both conditions. This discovery is significant because it may help explain why EEG patterns in COVID-19 patients resemble those seen in the early stages of neurodegenerative diseases like Alzheimer's.

Researchers believe this work could have a direct impact on patient care. They are advocating for routine EEG exams to detect early brain changes in both COVID-19 survivors and those at risk for cognitive decline.

"EEG patterns in COVID-19 patients resemble those seen in early neurodegenerative diseases," said Norris.

"These similarities may be due to shared issues such as brain inflammation, astrocyte activity, low oxygen levels and blood vessel damage," said Sompol.

By detecting these changes early, health care providers could potentially identify at-risk individuals sooner and implement interventions to prevent or slow the progression of cognitive decline.

As research continues, the team is particularly interested in how EEG monitoring can predict long-term outcomes in COVID-19 patients and assess the effectiveness of treatments aimed at preventing cognitive decline.

More information: Yang Jiang et al, Parallel electrophysiological abnormalities due to COVID‐19 infection and to Alzheimer's disease and related dementia, Alzheimer's & Dementia (2024). DOI: 10.1002/alz.14089

alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14089

[linguisticparadox]

Anyway did you know the current Parkinson's medication they give is literally the same thing they were giving over 50 years ago. Did you know it requires SWALLOWING and the only option if you develop impaired swallowing from The Disease That Impairs Your Swallowing is to start crushing it and adding it to applesauce and when that stops working the only thing left is to have a fucking tube surgically installed leading to your stomach. Did you know there is not even a version that can be given by IV!!!! There WAS an oral disintegrating tablet but the manufacturer fucking discontinued it. 🙃

And this medication has to be given MULTIPLE TIMES A DAY (there is an extended release version but it is prohibitively expensive so we only give it to dad before bed. Fun fact it does not last until morning!) and it loses effectiveness over time until eventually it just stops working.

(There is a new continuous subdermal pump version but it only just got FDA approval in the US and it will be at least 10 months before it's covered by Medicare, you know, the insurance that probably like 99% of Parkinson's patients in the US* rely on???????? Also iirc it's the same medication just a new delivery route so the issue of developing resistance still applies!!)

(Did I mention that Medicare also does not cover the cost of a nursing home lololol and THOSE AREN'T FUCKING CHEAP.)

Did you know Parkinson's can cause dementia symptoms including loss of executive functioning to the point that sufferers lose the ability to make decisions, which leaves them vulnerable to abuse? And that the medication does not help the cognitive symptoms???

Did you know patients' breathing remains intact so what kills them is usually smth like aspiration pneumonia, bedsores, or a serious fall?

Thank god for Michael J. Fox btw, it fucking sucks he has to deal with this but he has done SO MUCH to get new research funded, which is probably why we're just now having new breakthroughs like the pump or discovery of biomarkers that can be used to diagnose the disease before symptoms manifest.

Anyway I know there are a lot of causes needing our attention now but if you can it would be cool if you donated to the Michael J. Fox Foundation here:

* This is hyperbolic, I don't feel like looking up the actual number (if they even track it). Parkinson's mostly affects old ppl and in the US old ppl have Medicare ok.

Also all of this is possibly specific to the US but that's where I am and we are not moving to a Whole New Country just to squeeze a couple more years of misery out of my dad. ✌️

[axel-mania]

Huge discovery just came out. There is likely now a reliable biomarker for the disease I probably have, which has lead to nerve damage that has affected me in a variety of ways. Ehlers-Danlos is mainly known for being a genetic disease of improper collagen production, which ends up fucking with most body systems.

There are many subtypes, but the most common, hypermobile, had no genetic marker. This meant that it was almost impossible to get a diagnosis, with most doctors not even acknowledging its existence, and anyone without obvious enough dysfunction getting told they didn't "really" have EDS, just hypermobility, so there's no point in treating them. But now it seems that there is no such distinction between just hypermobility and EDS, as the same biomarker was found in the blood of everyone with that set of symptoms.

If we have an easy blood test a PCP can order to tell whether or not you have EDS, then things get easier as far as accessing specialists, getting disability payments, etc. But treatment is in a pretty bad place for us with or without a diagnosis, so it's not exactly a huge hurrah. Obviously plenty of genetic diseases with obvious markers are still associated with heavy medical malpractice and just getting told to exercise and take Tylenol. Still, this feels really good. I hope I live to get this test done.

[creativeera]

Cancer Biomarkers Market Poised to Exhibit a CAGR of 7.3% by 2031

Cancer biomarkers are substances whose presence is indicative of some biological condition, processes, or pathology. They can be used for cancer diagnosis or checking effectiveness of treatment. Being non-invasive procedures, demand for cancer biomarkers is growing rapidly. They aid in early detection of cancer during screening programs and reduce cost of cancer treatment. Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Key Takeaways Key players operating in the Cancer Biomarkers market are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. They are investing heavily in biomarker detection methods and panels targeting unmet clinical needs. Rising incidence of cancer across the world is driving for Cancer Biomarkers Market Demand. Biomarkers help in cancer screening and detecting disease at early stages. This improves treatment outcomes and survival rates significantly. Initiatives by governments and cancer councils to spread cancer awareness are also boosting the market. Global expansion strategies adopted by leading players are expected to support market growth during the forecast period. They are expanding their footprint in emerging markets of Asia Pacific, Latin America, and Middle East & Africa to tap the high growth opportunities. This will increase access to advanced cancer diagnostic solutions. Market Key Trends The use of artificial intelligence and machine learning algorithms to discover novel biomarkers from large datasets is a key trend in the market. It helps accelerate the process of biomarker identification. Genomic and proteomic biomarkers are also gaining traction for their role in cancer detection as well as tracking cancer progression and drug response. Development of personalized diagnostics based on multi-omics approaches and liquid biopsy tests are some other trends expected to shape the market.

Porter’s Analysis Threat of new entrants: The cancer biomarkers market requires huge capital investments in R&D for developing novel biomarkers and testing kits which makes the entry difficult for new players. Bargaining power of buyers: Buyers have moderate bargaining power in this market as there are many players offering similar cancer biomarker testing services. Bargaining power of suppliers: Suppliers have low bargaining power due to availability of alternative raw material suppliers in the market. Threat of new substitutes: Substitutes have low threat as there are limited substitutes available for cancer biomarker tests. Competitive rivalry: The market is highly competitive due to presence of many global as well as regional players. Geographical Regions North America region accounts for the largest share of the cancer biomarkers market in terms of value due to presence of major players, rising healthcare expenditure and increasing prevalence of cancer in the region. Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to increasing awareness regarding cancer, improving healthcare infrastructure and rising access to diagnostic services in emerging economies of China and India in this region.

Get more insights on Cancer Biomarkers Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[kingme1002]

RADICAL LIFE EXTENSION:

### Key Areas of Research and Approaches:

1. **Genetic Engineering**:

- **CRISPR and Gene Editing**: Technologies like CRISPR-Cas9 allow scientists to modify genes associated with aging and age-related diseases. By editing or repairing genes, it may be possible to slow down or reverse aging processes.

- **Telomere Extension**: Telomeres are protective caps at the ends of chromosomes that shorten with age. Research is exploring ways to extend or maintain telomere length to delay cellular aging.

2. **Senescence and Cellular Repair**:

- **Senolytics**: These are drugs designed to selectively eliminate senescent cells, which accumulate with age and contribute to tissue dysfunction and chronic diseases. Removing these cells can improve health and extend lifespan.

- **Stem Cell Therapy**: Stem cells have the potential to regenerate damaged tissues and organs. Research is ongoing to harness stem cells for repairing age-related damage and restoring function.

3. **Metabolic and Dietary Interventions**:

- **Caloric Restriction**: Studies have shown that reducing calorie intake without malnutrition can extend lifespan in various organisms. Researchers are investigating the mechanisms behind this and developing drugs that mimic the effects of caloric restriction.

- **Rapamycin and mTOR Inhibition**: Rapamycin, a drug that inhibits the mTOR pathway, has been shown to extend lifespan in animal models. It is being studied for its potential to delay aging in humans.

4. **Regenerative Medicine**:

- **Tissue Engineering**: Creating replacement tissues and organs using bioengineering techniques can address age-related degeneration and organ failure.

- **3D Bioprinting**: This technology allows for the creation of complex tissues and organs layer by layer, potentially providing replacements for damaged or aging body parts.

5. **Artificial Intelligence and Biotechnology**:

- **AI in Drug Discovery**: AI is being used to accelerate the discovery of new drugs and therapies for aging-related conditions.

- **Biomarkers of Aging**: Developing accurate biomarkers to measure biological age and the effectiveness of anti-aging interventions.

6. **Cryonics and Mind Uploading**:

- **Cryonics**: The practice of preserving bodies or brains at extremely low temperatures with the hope that future technology can revive and rejuvenate them.

- **Mind Uploading**: A speculative concept where a person's consciousness is transferred to a digital substrate, potentially allowing for indefinite existence in a virtual environment.

### Ethical and Societal Considerations:

- **Equity and Access**: Ensuring that life-extending technologies are accessible to all, not just the wealthy.

- **Overpopulation**: Addressing the potential impact on global population and resources.

- **Quality of Life**: Ensuring that extended life is accompanied by improved health and well-being, not just prolonged existence.

### Current Status:

While significant progress has been made in understanding the biology of aging, most radical life extension technologies are still in the experimental stages. Human trials are ongoing for some interventions, but widespread application is likely still years or decades away.

Radical life extension remains a highly interdisciplinary field, combining insights from genetics, biotechnology, medicine, and computational science. The ultimate goal is to not only extend human lifespan but to ensure that those additional years are lived in good health and vitality.

[darkmaga-returns]

The damage delivered by the COVID-19 vaccines is putting Insurance companies “in very serious trouble” due to the soaring death rates across the world.

According to a report from “Richard’s Substack,” the tsunami of death as a result of the shots will be soon followed by mass destruction of the economy.

“Governments, public health ministries and Big Pharma are not talking about what is coming – because they are deeply complicit in despicable, genocidal crimes – but there are a number of prominent, world-class medical scientists explaining what is in the cards over the next few years: a tsunami of death, due to the billions of so-called Covid-19 vaccines that were injected into hordes of victims in countries all over the world,” the report reads.

The article, which cites Dr. Dolores Cahill, says the mRNA vaccinated will be dead within three to five years, “even if they have had only one injection.”

Cahill’s 25 years of experience include work on how proteins and antibodies can be used in biomedical applications, including biomarker discovery, diagnostics, and personalized medicine.

Now, insurance companies, including the well-known “gecko” insurance company (we cannot name it for legal reasons), are on the brink of bankruptcy due to the burgeoning death rate.

[spacetimewithstuartgary]

DNA-like molecule may survive Venus-like cloud conditions

Punishing conditions in the clouds of Venus could be home to a DNA-like molecule capable of forming genes in life very different to that on Earth, according to a new study.

Long thought to be hostile to complex organic chemistry because of the absence of water, the clouds of Earth's sister planet are made of droplets of sulfuric acid, chlorine, iron, and other substances.

But research led by Wrocław University of Science and Technology shows how peptide nucleic acid (PNA)—a structural cousin of DNA—can survive under lab conditions made to mimic conditions that can occur in Venus' perpetual clouds.

The research is published in the journal Science Advances.

The international team drew on expertise from Cardiff University, Massachusetts Institute of Technology, Worcester Polytechnic Institute and industry collaborators Symeres for the study, which assessed PNA's ability to withstand a 98% sulfuric acid solution at room temperature for a period of two weeks.

Their findings add to the evidence that shows that concentrated sulfuric acid can sustain a diverse range of organic chemistry that might be the basis of a form of life different from Earth.

Lead author, Dr. Janusz Jurand Petkowski from Wrocław University of Science and Technology, said, "People think concentrated sulfuric acid destroys all organic molecules and therefore kills all life, but this is not true. While many biochemicals, like sugars, are unstable in such an environment, our research to date shows that other chemicals found in living organisms, such as nitrogenous bases, amino acids, and some dipeptides, don't break down.

"Here, we've started a new chapter on the potential of sulfuric acid as a solvent for life, demonstrating that PNA—a complex molecule, structurally related to DNA, and known to interact specifically with nucleic acids—exhibits remarkable stability in concentrated sulfuric acid at room temperature."

The work builds on findings from mid-2020, where a team of scientists from Imperial College London presented evidence for the presence of phosphine, a toxic gas produced in oxygen-poor environments, on Venus.

In the same year, a group of scientists from Cardiff University shared preliminary results from their research indicating the presence of ammonia on the planet.

Dr. William Bains from Cardiff University's School of Physics and Astronomy was part of both studies.

He added, "Both ammonia and phosphine are biomarkers, which means they can indicate the presence of life. But Venus's clouds are utterly hostile to life as we know it on Earth. So our latest study seeks to explore the potential of concentrated sulfuric acid as a solvent that could support the complex chemistry needed for life in these seemingly uninhabitable clouds.

"To find that PNA with its similarities to DNA can remain in concentrated sulfuric acid for hours is quite astonishing. It's a new piece of a much larger puzzle in our understanding of how life, albeit very different from ours, is made and where in the universe it might exist."

The findings also offer new ways of understanding the chemistry of sulfuric acid, one of the most widely used industrial chemicals, that may have practical use in the future, according to the team.

Dr. Pętkowski added, "Our study shows that PNA is no longer stable in sulfuric acid at temperatures higher than 50°C. So, our future research will focus on creating a genetic polymer—a molecule that can play the role that DNA plays in life on Earth—that is stable in concentrated sulfuric acid over the temperature range of Venus's clouds, between 0°C and 100°C, and not just at room temperature.

"The discoveries so far are therefore only the first step towards finding such a stable polymer."

IMAGE: PNA hexamers and monomers.(A) PNA hexamers composed of six identical, consecutive units of nucleic acid bases: adenine (A6), guanine (G6), cytosine (C6), and thymine (T6). PNA backbone (AEG) residues are colored in red, the acetyl linker residues are in pink, and the nucleic acid bases are in blue. (B) Structures of PNA monomers, mA, mG, mC, and mT. Credit: Science Advances (2025). DOI: 10.1126/sciadv.adr0006

[dertaglichedan]

Blood test could detect Parkinson’s disease before symptoms emerge

Researchers have developed a simple and “cost-effective” blood test capable of detecting Parkinson’s disease long before symptoms emerge, according to a study.

About 153,000 people live with Parkinson’s in the UK, and scientists who undertook the research said the test could “revolutionise” an early diagnosis of Parkinson’s disease, “paving the way for timely interventions and improved patient outcomes”.

Parkinson’s is a progressive neurological condition in which nerve cells in the brain are lost over time. This leads to a reduction of the chemical dopamine which plays an important part in controlling movement.

This new test, which the Times reports costs £80, analyses small pieces of genetic material known as transfer RNA fragments (tRFs) in the blood, focusing on a repetitive RNA sequence that accumulates in Parkinson’s patients.

It also looks at a parallel decline in mitochondrial RNA, which deteriorates as the disease progresses. Mitochondria exist inside cells and generate energy.

By measuring the ratio between these biomarkers, researchers said the test “offers a highly accurate, non-invasive, rapid and affordable diagnostic tool, providing hope for early interventions and treatments that could change the course of the disease”.

On a scale where a score of 1 indicates a perfect test while 0.5 shows the test is no better than flipping a coin, the test scored 0.86, the Times reported.

The best clinical tests presently used on patients showing early signs of the disease scored 0.73, according to the study published in the journal Nature Aging.

The test uses the same PCR technology used during the pandemic to confirm Covid cases. It works by amplifying the genetic material being targeted, which allows it to be detected.

“This discovery represents a major advancement in our understanding of Parkinson’s disease and offers a simple, minimally invasive blood test as a tool for early diagnosis,” said Prof Hermona Soreq of the Hebrew University of Jerusalem, who supervised the study. “By focusing on tRFs, we’ve opened a new window into the molecular changes that occur in the earliest stages of the disease.”

Prof David Dexter, director of research at Parkinson’s UK, said: “This research represents a new angle to explore in the search for a biological marker for Parkinson’s. In this case the marker can be identified and measured in the blood which makes it attractive for a future patient-friendly diagnostic test for Parkinson’s.

“More work is needed to continue to test and validate this possible test, especially understanding how it can distinguish between other conditions that have similar early signs to Parkinson’s.”